Glossary
The State of Metabolic Health in America, 2026 Baseline Edition
Definitions of key terms used in this report. Where a term has a standard clinical or regulatory definition, that definition is used. Where definitions vary by source, the definition used in this report is stated and the source is noted.
- Cardio-kidney-metabolic (CKM) syndrome
- A term introduced by the American Heart Association in 2023 to describe the interconnected pathophysiology of cardiovascular disease, chronic kidney disease, and metabolic conditions including obesity and type 2 diabetes.
- Clinical outcome
- A change in a patient's health status, such as HbA1c reduction, weight loss, or blood pressure control. Distinguished from utilization and cost outcomes in this report.
- Employer-sponsored insurance (ESI)
- Health insurance coverage provided through an employer, covering the employee and often dependents. The primary source of health coverage for working-age adults in the United States.
- GLP-1 receptor agonist
- A class of medications that mimic the glucagon-like peptide-1 hormone, used to treat type 2 diabetes and obesity. Examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
- Metabolic health
- A state in which key metabolic markers — including blood glucose, blood pressure, triglycerides, HDL cholesterol, and waist circumference — are within normal ranges without the use of medication.
- Metabolic syndrome
- A cluster of conditions — elevated blood glucose, high blood pressure, excess abdominal fat, high triglycerides, and low HDL cholesterol — that occur together and increase the risk of cardiovascular disease and type 2 diabetes.
- Prediabetes
- A condition in which blood glucose levels are higher than normal but not yet high enough to be classified as type 2 diabetes. Defined by the CDC as a fasting glucose of 100–125 mg/dL or an HbA1c of 5.7–6.4%.
- Utilization outcome
- A change in the use of health care services, such as emergency department visits, hospitalizations, or prescription fills. Distinguished from clinical outcomes in this report.